Paroxysmal Nocturnal Hemoglobinuria Treatment Market | Global Industry Report 2023

The global paroxysmal nocturnal hemoglobinuria treatment market size was valued at USD 6.4 billion in 2022 and is poised to grow at a significant CAGR of 6.2% during the forecast period 2023-29. The primary factors that drive the market are the growing prevalence of hematologic disorders across the world, rising research and development activities with continuously rising healthcare infrastructure and increasing demand for novel drugs and therapies in the market.

View the detailed report description here https://www.precisionbusinessinsights.com/market-reports/paroxysmal-nocturnal-hemoglobinuria-treatment-market

The global paroxysmal nocturnal hemoglobinuria treatment market is segmented based on treatment, drug types, distribution channel, and geography.

Based on the treatment, the market is segmented into the following:
• Stem Cell Transplant
• Blood Transfusion

Based on the drug types, the market is segmented into the following:
• Anti C5 monoclonal antibodies
o Eculizumab
o Ravulizumab
• Danicopan
• Iron supplements
• others

Based on the distribution channel, the market is segmented into the following:
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Based on the region, the market is segmented into the following:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Based on treatment type, stem cell transplant holds the highest market share. The major factor for the rise of this segment is that the use of stem cell transplant gives effective results in hematologic disorder treatment, increasing incidences of hematological disorders across the globe such as anemia, bleeding disorders such as hemophilia, blood clots, and blood cancers such as leukemia, lymphoma, and myeloma seen common in the present era, demand efficient treatment influence the market growth. The technological advancement and undergoing clinical trials drugs are offers specific therapies contributing to market development along with government initiatives for better treatment facilities drive the market growth at a significant rate.

Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market
Asia Pacific region is expected to grow significantly in the global Paroxysmal Nocturnal Hemoglobinuria Treatment Market size over the forecast period It is attributed to the increasing incidence of blood disorders in countries like China, India, and Japan consequences rise in demand for specific treatment. Thalassemia is commonly seen in the Asian population it is a type of blood disorder that results from the coinheritance of beta-thalassemia and HbE. Japan is poised to post a higher CAGR in the forecast period owing to the well-developed healthcare infrastructure in the region.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the Key Strategies Adopted by Market Players
The global Paroxysmal Nocturnal Hemoglobinuria Treatment Market further reveals that the key players are implementing strategies such as the extension of product collection through research and development activities, product launches, acquisitions, mergers, and strategic alliances to improve their market position and strengthening the market revenue share.

In December 2022, Novartis announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary endpoint.

Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=196260

Key players' profiles in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market report are Novartis AG, Apellis Pharmaceuticals, AbbVie, Allergan, Novartis AG, Johnson & Johnson, Bayer AG, Takeda Pharmaceuticals, Bristol-Myers Squibb Company, Mylan N.V., Amgen Inc., Alexion Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Amgen Inc., GE Healthcare, Ra Pharmaceuticals, Regeneron Pharmaceuticals, Inc., and Thermo Fisher Scientific Inc.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.